FDA approves cabozantinib to treat rare type of thyroid cancer

News
Article

FDA has approved cabozantinib (Cometriq, Exelixis and AstraZeneca) for the treatment of progressive, metastatic medullary thyroid cancer (MTC).

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Recent Videos
Related Content
© 2025 MJH Life Sciences

All rights reserved.